Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction
|ClinicalTrials.gov Identifier: NCT01514214|
Recruitment Status : Completed
First Posted : January 23, 2012
Last Update Posted : May 2, 2018
Strictures in the bile duct cause a blockage of flow of bile. This leads to potential problems including jaundice, itch and infection in the bile duct. The usual first step in this situation would be to allow flow of bile by placing a stent across the stricture. This is usually done by a special type of endoscopy procedure called an endoscopic retrograde cholangiopancreatography, or ERCP.
The most commonly used stent are made from a plastic material called polyethylene and has a central lumen in which bile drains through it. Health Canada has approved the sale and use of another stent with a winged perimeter (the VIADUCT stent) for placement in bile duct strictures and is used routinely in our hospitals. However, the investigators do not know which stent is better at treating bile duct strictures. In order to determine which stent would be more useful, the VIADUCT stent and the usual polyethylene flanged stent must be studied under carefully controlled circumstances. This will be done by a randomized, subject-blinded study. Other trials in the past have looked at other stents in this way, but this is the first time the VIADUCT stent has been looked at in this manner. The investigators suspect that the design of the VIADUCT stent will allow it to work for a longer period of time compared to the traditional polyethylene stent.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Tumor of Extrahepatic Bile Duct||Device: WInged perimeter biliary stent insertion (Viaduct) Device: traditional polyethylene stent insertion (Cotton Huibregtse)||Not Applicable|
Biliary obstruction usually presents with jaundice, pruritis, cholangitis, and steatorrhoea. Strictures which are a common cause of biliary obstruction, may be secondary to benign or malignant conditions. Common benign conditions include chronic pancreatitis, primary sclerosing cholangitis, autoimmune pancreatitis, prior surgery and recurrent pyogenic cholangitis. Cholangiocarcinomas, ampullary and pancreatic tumours are more common causes of malignant biliary obstruction.
The principles of managing biliary strictures are to determine the underlying cause of the stricture, whilst achieving drainage of the biliary tree, initially with the placement of a plastic stent via an endoscopic retrograde cholangiopancreatography (ERCP). Strictures are sampled using biliary brush cytology and/or biliary biopsy to assess for underlying malignancy. Malignant strictures are usually staged for resectability with computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS).
The Viaduct stent (GI Supply, Camp Hill, Pennsylvania, USA) is a unique stent design and has a winged perimeter, which channels flow of bile around the stent, rather than through a central lumen. Theoretically this may enhance flow and biliary drainage, and prevent obstruction. Both polyethylene and Viaduct plastic stents are approved for use by Health Canada for benign and malignant biliary conditions. It is not known whether one stent is superior to the other in maintaining symptomatic relief from bile duct strictures as there have been no studies to date comparing the two stents.
There is limited published data on the Viaduct stent. A pilot study of the winged stent design was published in 2006. Five patients had winged stents inserted and followed for 2 weeks. The were no problems with stent insertion and symptoms of obstruction and jaundice improved over this time. One study published in abstract form retrospectively compared 34 Viaduct stents matched with 240 "conventional" stents over a five year period. There was no statistical difference with stent dysfunction, and a trend towards patency with the Viaduct stent.
The primary aim of this study is to compare the stent patency time in the Viaduct and polyethylene stent groups in subjects with malignant bile duct strictures. The secondary aims are to determine the etiology of stent failure in the two treatment groups, to identify and compare device-related adverse events in the two treatment groups, to identify other patient factors associated with stent failure, and to compare survival between the Viaduct and polyethylene stent groups.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||58 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized Trial Comparing a Winged Perimeter Stent and Traditional Polyethylene Plastic Stent in the Management of Malignant Distal Biliary Strictures|
|Actual Study Start Date :||January 2012|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||September 2016|
Active Comparator: Winged perimeter stent
Patients who receive the Viaduct stent during ERCP
Device: WInged perimeter biliary stent insertion (Viaduct)
Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
Other Name: Viaduct Stent
Active Comparator: polyethylene stent arm
Patient who receive the traditional polyethylene stent during ERCP
Device: traditional polyethylene stent insertion (Cotton Huibregtse)
insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
Other Name: Cotton Huibregtse Stent
- Stent patency time [ Time Frame: six months post stent insertion ]Time to bile duct re-obstruction
- Etiology of stent failure [ Time Frame: six months post stent insertion ]Usually occlusion or migration
- Compare number of patients with device related adverse events [ Time Frame: six months post stent insertion ]Comparing both procedural and delayed complications of stents
- Identify patient factors associated with stent failure [ Time Frame: six months post stent insertion ]
- Survival between the two groups [ Time Frame: six months post stent insertion ]Measurement in months of survival post diagnosis
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514214
|Canada, British Columbia|
|Vancouver General Hospital|
|Vancouver, British Columbia, Canada, V5Z 1M9|
|St Paul's Hospital|
|Vancouver, British Columbia, Canada, V6Z 2K5|
|Principal Investigator:||Jennifer J Telford, MD MPH FRCPC||University of British Columbia|